The PAWS Pet Company’s (PraXsyn) 10K was filed this afternoon.

PALO ALTO, CA, April 23, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announces that its 10K filing was submitted to the SEC this afternoon. “We would like to thank our auditors and our financial team that worked around the clock to get it done,” said Dan Wiesel, CEO of The PAWS Pet Company. “With the 10K complete, we are looking forward to filing the 10Q which will incorporate the results of our new merger partner Mesa Pharmacy”.

 

Our goal at the new PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.

 

About PraXsyn, Inc.

PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams and ointments in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries. In the near future, we will be instituting our Point of Care/In-Office Dispensing Program, and our In-Office Toxicology Testing. As the medical industry changes, PraXsyn will be there to provide different delivery systems.

For additional information go to www.praxsyn.com? 

Company Contact: ir@praxsyn.com

 

Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.